Literature DB >> 11338314

Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke?

O H Klungel1, B H Stricker, M M Breteler, J C Seidell, B M Psaty, A de Boer.   

Abstract

The results from several nonexperimental studies suggest that drug treatment of hypertension in daily clinical practice may not be as effective as in randomized controlled trials. These nonexperimental studies had limitations with regard to the selection of an appropriate control group. The objective of our study was to assess the effect of drug treatment of hypertension under circumstances of everyday medical practice on the incidence of stroke by using a prognostically comparable untreated reference group. Within two prospective, population-based cohort studies among 45,000 men and women 20 years of age and older in the Netherlands, we selected a cohort of 2,301 hypertensive subjects who either received drug treatment for hypertension (N = 1,318) or were untreated for hypertension but were determined to be "candidates" for drug treatment on the basis of their level of blood pressure and the presence of other cardiovascular risk factors (N = 983). Follow-up averaged 4.6 years and was complete for 91% of the hypertensives. Compared with untreated hypertensive subjects who were "candidates" for drug treatment, subjects who received drug treatment for hypertension had, after adjustment for potential confounders, a 39% [95% confidence interval (CI) = 3-61%] reduced risk of stroke. About 46 (95% CI = 29-599) hypertensive patients need to be treated with antihypertensive drugs for 5 years to prevent one stroke in the general Dutch population. When a prognostically comparable reference group is used, the drug treatment of hypertension under circumstances of everyday medical practice appears to be effective in the reduction of the incidence of stroke. The relative risk reduction that we found was similar to those found in randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11338314     DOI: 10.1097/00001648-200105000-00014

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  4 in total

1.  Effectiveness of dental services in facilitating recovery from oral disadvantage.

Authors:  Monica A Fisher; Gregg H Gilbert; Brent J Shelton
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

2.  Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men.

Authors:  Paul Hommerson; Srecko I Nedeljkovic; Olaf H Klungel; Anthonius de Boer; Miodrag C Ostojic; Miodrag Z Grujic; Nikola M Vojvodic; Bennie P M Bloemberg; Daan Kromhout
Journal:  Pharm World Sci       Date:  2005-04

Review 3.  Cardiovascular risk in patients receiving antihypertensive drug treatment from the perspective of endothelial function.

Authors:  Tatsuya Maruhashi; Yukihito Higashi
Journal:  Hypertens Res       Date:  2022-05-20       Impact factor: 5.528

4.  Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project.

Authors:  Victoria Abbing-Karahagopian; Xavier Kurz; Frank de Vries; Tjeerd P van Staa; Yolanda Alvarez; Ulrik Hesse; Joerg Hasford; Liset van Dijk; Francisco J de Abajo; John G Weil; Lamiae Grimaldi-Bensouda; Antoine C G Egberts; Robert F Reynolds; Olaf H Klungel
Journal:  Curr Clin Pharmacol       Date:  2014-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.